671212-34-3

Basic information

• Product Name: (2-[4-BENZYL-PIPERAZIN-1-YL]-2-OXO-ETHYL)-CARBAMIC ACID TERT-BUTYL ESTER
• Synonyms: (2-[4-BENZYL-PIPERAZIN-1-YL]-2-OXO-ETHYL)-CARBAMIC ACID TERT-BUTYL ESTER;4-BENZYL-1-(BOC-AMINO-ACETYL)-PIPERAZINE;tert-butyl (4-benzylpiperazin-1-yl)carbonylcarbamate;(2-[4-Benzyl-piperazin-1-yl]-2-oxo-ethyl)-carbamic;tert-Butyl 2-(4-benzylpiperazin-1-yl)-2-oxoethylcarbamate
• CAS NO: 671212-34-3
• Molecular Formula: C₁₈H₂₇N₃O₃
• Molecular Weight: 333.43
• Product Categories: piperazines
• Mol File: 671212-34-3.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 490.8°C at 760 mmHg
• Flash Point: 250.6°C
• Appearance: /
• Density: 1.137g/cm³
• Vapor Pressure: 8.86E-10mmHg at 25°C
• Refractive Index: 1.543
• CAS DataBase Reference: (2-[4-BENZYL-PIPERAZIN-1-YL]-2-OXO-ETHYL)-CARBAMIC ACID TERT-BUTYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: (2-[4-BENZYL-PIPERAZIN-1-YL]-2-OXO-ETHYL)-CARBAMIC ACID TERT-BUTYL ESTER(671212-34-3)
• EPA Substance Registry System: (2-[4-BENZYL-PIPERAZIN-1-YL]-2-OXO-ETHYL)-CARBAMIC ACID TERT-BUTYL ESTER(671212-34-3)

Safety Data

• Hazardous Substances Data: 671212-34-3(Hazardous Substances Data)

Usage

General Description

(2-[4-Benzyl-piperazin-1-yl]-2-oxo-ethyl)-carbamic acid tert-butyl ester is a chemical compound used in the pharmaceutical industry. It is a carbamate derivative with a tert-butyl ester functional group. (2-[4-BENZYL-PIPERAZIN-1-YL]-2-OXO-ETHYL)-CARBAMIC ACID TERT-BUTYL ESTER has potential as a drug intermediate or as a building block in the synthesis of bioactive molecules. The benzyl-piperazin-1-yl group contributes to the compound's pharmaceutical activity, making it a potential candidate for drug development. However, further research and testing are needed to determine its specific medical applications and safety profile.

InChI:InChI=1/C18H27N3O3/c1-18(2,3)24-17(23)19-13-16(22)21-11-9-20(10-12-21)14-15-7-5-4-6-8-15/h4-8H,9-14H2,1-3H3,(H,19,23)

Upstream product

• 4530-20-5 BOC-glycine 
• 2759-28-6 1-phenylmethylpiperazine 

Downstream Products

• 1220018-02-9 2-amino-1-(4-benzylpiperazin-1-yl)ethanone dihydrochloride 
• 1416064-34-0 C₁₉H₂₉N₃O₂ 
• 831251-75-3 C₂₁H₂₄ClN₃O₂ 
• 25443-91-8 N-[2-(4-Benzyl-piperazin-1-yl)-2-oxo-ethyl]-2-phenyl-acetamide 
• 1299424-21-7 C₂₁H₃₁N₃O₂ 
• 744226-61-7 C₂₀H₂₃N₃O₂ 
• 433262-34-1 C₂₀H₂₉N₃O₂ 
• 361979-30-8 2-amino-1-(4-benzylpiperazin-1-yl)ethan-1-one 
• 1060944-73-1 C₂₄H₃₃N₃O₂ 
• 887198-35-8 C₂₅H₃₅N₃O₂ 
• 671212-41-2 {2-[4-(4-fluoro-benzenesulfonyl)-piperazin-1-yl]-2-oxo-ethyl}-carbamic acid tert-butyl ester 
• 671212-38-7 [2-(4-benzoyl-piperazin-1-yl)-2-oxo-ethyl]-carbamic acid tert-butyl ester 
• 671212-25-2 2-amino-1-[4-(4-fluoro-benzenesulfonyl)-piperazin-1-yl]-ethanone 
• 671212-20-7 2-amino-1-(4-benzoyl-piperazin-1-yl)-ethanone 

Relevant articles and documents

Inhibition of Ebola virus infection: Identification of niemann-pick C1 as the target by optimization of a chemical probe

A high-throughput screen identified adamantane dipeptide 1 as an inhibitor of Ebola virus (EboV) infection. Hit-to-lead optimization to determine the structure-activity relationship (SAR) identified the more potent EboV inhibitor 2 and a photoaffinity labeling agent 3. These antiviral compounds were employed to identify the target as Niemann-Pick C1 (NPC1), a host protein that binds the EboV glycoprotein and is essential for infection. These studies establish NPC1 as a promising target for antiviral therapy.

Structure-activity relationship studies on unifiram (DM232) and sunifiram (DM235), two novel and potent cognition enhancing drugs

Structure-activity relationships on two novel potent cognition enhancing drugs, unifiram (DM232, 1) and sunifiram (DM235, 2), are reported. Although none of the compounds synthesised reached the potency of the parent drugs, some fairly active compounds have been identified that may represent new leads to develop other cognition enhancing drugs. An interesting result of this research is the identification of two compounds (13 and 14) that are endowed with amnesing activity (the opposite of the activity of the original molecules) and are nearly equipotent to scopolamine. Moreover, two compounds of the series (5 and 6) were found endowed with analgesic activity on a rat model of neuropathic pain at the dose of 1 mg/kg.